Skip to Main Content

Author Details

Massimo Serra
IRCCS Istituto Ortopedico Rizzoli
1989
170
54
PMIDPaper TitleJournal TitlePublished Year
36614241Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.Int J Mol Sci2023
37596165Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma.Cancer Epidemiol2023
36614241Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.Int J Mol Sci2023
37108089Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need.Int J Mol Sci2023
37596165Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma.Cancer Epidemiol2023
37108089Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need.Int J Mol Sci2023
35201621Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).Cancer2022
36233089Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.Int J Mol Sci2022
36352194Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis.Cell Oncol (Dordr)2022
36149602ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis.Cell Oncol (Dordr)2022
35172717miR-486-5p expression is regulated by DNA methylation in osteosarcoma.BMC Genomics2022
35201621Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).Cancer2022
36149602ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis.Cell Oncol (Dordr)2022
36233089Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.Int J Mol Sci2022
36352194Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis.Cell Oncol (Dordr)2022
35172717miR-486-5p expression is regulated by DNA methylation in osteosarcoma.BMC Genomics2022
34207685Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.Cancers (Basel)2021
34207685Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.Cancers (Basel)2021
34572110Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?Cells2021
34572110Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?Cells2021
32155954ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.Cells2020
32191290Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.JAMA Oncol2020
32398946Long-Term Follow-up of a Randomized Study of Oral Etoposide versus <i>Viscum album</i> Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse.Sarcoma2020
32295254Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.Cells2020
32155954ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.Cells2020
32211337Cisplatin Resistance in Osteosarcoma: <i>In vitro</i> Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments.Front Oncol2020
32473836Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment.Biochem Pharmacol2020
32599901Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.Int J Mol Sci2020
32629971Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.Int J Mol Sci2020
32629971Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.Int J Mol Sci2020
32599901Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.Int J Mol Sci2020
32473836Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment.Biochem Pharmacol2020
32211337Cisplatin Resistance in Osteosarcoma: <i>In vitro</i> Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments.Front Oncol2020
32295254Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.Cells2020
32398946Long-Term Follow-up of a Randomized Study of Oral Etoposide versus <i>Viscum album</i> Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse.Sarcoma2020
32191290Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.JAMA Oncol2020
30430199Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.Cell Mol Life Sci2019
30430199Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.Cell Mol Life Sci2019
30822170Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.Expert Opin Drug Metab Toxicol2019
31401903An update on emerging drugs in osteosarcoma: towards tailored therapies?Expert Opin Emerg Drugs2019
31047947Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.Cancer Lett2019
31401903An update on emerging drugs in osteosarcoma: towards tailored therapies?Expert Opin Emerg Drugs2019
30822170Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.Expert Opin Drug Metab Toxicol2019
31047947Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.Cancer Lett2019
29210060Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.Int J Cancer2018
29933048Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines.Cancer Lett2018
30324828Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?Expert Rev Mol Diagn2018
30463350Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma.Int J Mol Sci2018
29473324Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice.Cancer Med2018
29210060Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.Int J Cancer2018
  • 1 - 50 of 340

Recommended Authors

Radoslav Davidovic
Institute of Nuclear Sciences Vinca, University of Belgrade
Career Start Year 2012
Number of shared co-authors 0
Ana Teresa Amaral
Instituto de Salud Carlos III
Career Start Year 2009
Number of shared co-authors 9
Wendong Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 2
Kjetil Boye
Oslo University Hospital
Career Start Year 2007
Number of shared co-authors 9
Arun S Singh
University of California-Los Angeles
Career Start Year 2006
Number of shared co-authors 1
Joseph A Ludwig
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 10
Arnulfo Mendoza
National Cancer Institute, National Institutes of Health
Career Start Year 2004
Number of shared co-authors 7
Sandra J Strauss
University College London, Cancer Institute
Career Start Year 2003
Number of shared co-authors 16
Ken Kikuchi
Kyoto Prefectural University of Medicine
Career Start Year 2002
Number of shared co-authors 2
Sung Wook Seo
Samsung Medical Center, Sungkyunkwan University
Career Start Year 2001
Number of shared co-authors 0
Jilong Yang
Tianjin Medical University Cancer Institute and Hospital
Career Start Year 2000
Number of shared co-authors 0
Beate Rinner
Medical University of Graz
Career Start Year 2000
Number of shared co-authors 7
Oscar M Tirado
Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)/CIBERONC
Career Start Year 2000
Number of shared co-authors 13
Tadashi Kondo
Nagasaki University Graduate School of Biomedical Sciences
Career Start Year 1997
Number of shared co-authors 3
Najat C Daw
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 7
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 4
Uta Dirksen
University Hospital Essen, West German Cancer Center
Career Start Year 1994
Number of shared co-authors 33
Jeremy Whelan
University College London Hospitals NHS Foundation Trust
Career Start Year 1991
Number of shared co-authors 19
Eberhard Korsching
Institutet of Bioinformatics, University Hospital of Munster, University of Munster
Career Start Year 1990
Number of shared co-authors 10
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 6
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 0
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 1
Choh Yeung
Center for Cancer Research, National Cancer Institute
Career Start Year 1987
Number of shared co-authors 6
Silvano Bosari
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Career Start Year 1986
Number of shared co-authors 0
Fran??oise R??dini
Nantes Universite, Inserm UMR 7, CNRS UMR 6075, Universite d'Angers
Career Start Year 1986
Number of shared co-authors 15
David M Loeb
Children's Hospital at Montefiore.
Career Start Year 1986
Number of shared co-authors 5
Susan A Burchill
Leeds Institute of Medical Research, St. James's University Hospital
Career Start Year 1986
Number of shared co-authors 9
Jeffrey A Toretsky
Georgetown University Medical Center, Georgetown University
Career Start Year 1986
Number of shared co-authors 20
Francis J Hornicek
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
Career Start Year 1983
Number of shared co-authors 3
Adrian L Harris
University of Oxford
Career Start Year 1981
Number of shared co-authors 7

Collaborators

Katia Scotlandi
IRCCS Istituto Ortopedico Rizzoli
Co-authored papers 92
Piero Picci
IRCCS Istituto Ortopedico Rizzoli
Co-authored papers 90
Claudia Maria Hattinger
IRCCS Istituto Ortopedico Rizzoli
Co-authored papers 54
Sakari Knuutila
Co-authored papers 13
Chiara Riganti
University of Turin
Co-authored papers 10
Ola Myklebost
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 9
Ana Pati??o-Garc??a
Center for Applied Medical Research.
Co-authored papers 8
Lisa Mirabello
National Cancer Institute
Co-authored papers 7
Richard Gorlick
University of Texas MD Anderson Cancer Center
Co-authored papers 7
Sharon A Savage
Clinical Genetics Branch, National Cancer Institute (NCI)
Co-authored papers 7
Fernando Lecanda
University of Navarra, Center for Applied Medical Research
Co-authored papers 7
Adrienne M Flanagan
University College London, UCL Cancer Institute
Co-authored papers 7
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 7
Logan G Spector
Division of Epidemiology and Clinical Research, University of Minnesota
Co-authored papers 6
Jay S Wunder
University of Toronto
Co-authored papers 6
Irene L Andrulis
University of Toronto
Co-authored papers 6
David M Thomas
Garvan Institute of Medical Research
Co-authored papers 6
Meredith Yeager
Frederick National Laboratory for Cancer Research
Co-authored papers 6
Donald A Barkauskas
Keck School of Medicine of the University of Southern California
Co-authored papers 6
Julie M Gastier-Foster
Baylor College of Medicine
Co-authored papers 6
Margaret A Tucker
National Cancer Institute
Co-authored papers 6
Roberto Tirabosco
University College London, UCL Cancer Institute
Co-authored papers 6
Robert N Hoover
National Cancer Institute
Co-authored papers 5
Nalan Gokgoz
Lunenfeld-Tanenbaum Research Institute
Co-authored papers 5
Fernanda Amary
Royal National Orthopaedic Hospital
Co-authored papers 5
Luis Sierrases??maga
Clinica Universidad de Navarra
Co-authored papers 4
Zhaoming Wang
St Jude Children's Research Hospital
Co-authored papers 4
Neyssa Marina
Stanford University School of Medicine
Co-authored papers 4
Joseph F Fraumeni
National Cancer Institute
Co-authored papers 4
Silvia Regina Caminada de Toledo
Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo
Co-authored papers 4
Release 1.2